🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
The scoreboard, the stakes, and why triage was only the opening act
Viz.ai, the company that taught hospitals to pay for a phone notification
RapidAI, the evidence company that owns the stroke suite
Aidoc, the operating system bet and the foundation model swing
The reimbursement plot twist: SaMS, NTAP nostalgia, and a bill stuck in committee
The scorecard, and why Aidoc gets the slight nod
What could flip it
Abstract
Three companies dominate the acute imaging AI conversation in the US: Viz.ai, RapidAI, and Aidoc. All three now claim roughly 2,000 hospitals, all three call themselves platforms, and all three still make most of their money finding strokes and clots. This piece walks through each company’s origin, product, evidence base, capital position, and go-to-market as of late September 2026, then overlays the thing that changes the math: the CY2027 Medicare proposed rules that create a Software as a Medical Service payment category, plus a pending Senate bill that would park algorithm-based services in New Technology APCs for five years. The conclusion gives Aidoc a slight edge, because a foundation model that cleared a double-digit set of indications in one FDA submission, a war chest north of half a billion dollars, a former AMA president running clinical strategy, and a twelve-system evidence consortium add up to the best position for a market that is about to start paying for software per case. Viz.ai keeps the best clinical brand and the only real pharma revenue line. RapidAI keeps the best evidence and the deepest stroke franchise. Both have credible paths to flipping the order, and the last section lays them out.
